January 18, 2024

Trial for Patients 75 and Older with Diffuse Large B-Cell Lymphoma Helps Address Care Inequities

Multiple Cleveland Clinic sites to participate in National Cancer Institute trial comparing treatment regimens for newly diagnosed patients

Treating older patients with diffuse large B-cell lymphoma (DLBCL)

Diffuse large B-cell lymphoma (DLBCL) is curable in roughly 60% of cases, yet an estimated 10-15% of patients 80+ years old with the disease receive no treatment, due to concerns about tolerance to the combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) that is standard of care for younger patients. To address this issue, Cleveland Clinic has joined a phase 2/3 National Cancer Institute (NCI) trial investigating treatment options specifically for older patients.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

This nationwide trial is studying the safety and efficacy of using reduced doses of CHOP chemotherapy and standard doses of rituximab (“R-mini-CHOP”) compared to the same combination with the addition of the oral chemotherapy azacitidine (“R-mini-CHOP + aza”).

Study background

Nearly one third of patients with DLBCL are 75 years or older – an age group that is severely under-represented in cancer clinical trials. Although older adults make up more than 40 percent of the overall population with cancer, fewer than 10% of patients in this age group participate in NCI-sponsored clinical trials.

This is due to a number of factors, including:

  • Trial criteria that excludes older patients and/or those with comorbidities
  • Barriers such as transportation issues that can disproportionately impact older patients
  • Misconceptions among physicians and others about older patients’ willingness to participate in trials

Despite FDA guidance on enrolling older adults in cancer studies and calls in the medical community to broaden eligibility criteria, age disparities persist.

“Older patients are not frequently studied but this is a large portion of people who need improved outcomes and it makes sense to prioritize this study,” says Allison Winter, MD, an oncology and hematology specialist at Cleveland Clinic’s Taussig Cancer Center and a collaborator on the NCI trial.


Room for improvement in treating older patients

A previous phase 2 trial of full-dose rituximab and reduced-dose CHOP in older patients with DLBCL found a two-year progression-free survival of 47% and a two-year overall survival of 59%. “That is definitely less than we would expect in younger populations, which shows there is room for improvement,” says Dr. Winter.

The next step is to study whether the addition of azacitidine to this regimen improves efficacy and is well tolerated. “Azacitidine is already used to treat older patients with myelodysplastic syndrome and acute leukemia, so we know that it is tolerated in and there’s also scientific rationale for why it might be helpful in patients with diffuse large B-cell lymphoma.”

Eligibility criteria

Newly diagnosed patients with DLBCL who are age 75 or greater with a performance or ECOG status of 0-2 may be eligible for the study. Patients with grade 3B follicular lymphoma, high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements may also be eligible.

Often comorbidities such as coronary artery disease, renal disease and diabetes automatically exclude patients from trials, but that is not the case in this instance. Patients with comorbidities are still eligible, with the exception of those with active cardiac disease within 26 weeks prior to trial registration. See clinicaltrials.gov for additional eligibility criteria.

Referring physicians are encouraged to reach out for a virtual or in-person consult if they have a patient who may be eligible for the trial.


Study details

Study participants are randomized to one of two arms (R-mini-CHOP or R-mini-CHOP + aza), receiving the given treatment for up to six cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients will be followed periodically up to five years from the date of trial registration. The trial has completed the safety run in phase 1 and is enrolling into the phase 2 portion of the trial. There are already 69 patients enrolled. This study is open at many other cancer centers around the country.

Making trials more convenient

To improve accessibility, Cleveland Clinic is making it possible for patients to participate in the trial at the main campus or at one of the below locations across Ohio.

  • Fairview
  • Hillcrest
  • Independence
  • Mansfield
  • Sandusky
  • South Pointe
  • Strongville
  • Wooster

Patients who have issues getting to/from clinic appointments can connect with a social worker who can provide transportation and other supportive services.

Ultimately, the investigators hope the insights gained through the study will help to broaden their understanding and ability to treat older populations facing DLBCL and similar diseases.

Related Articles

23-CNR-4221120 ASH 2023 Graphics-CQD
December 4, 2023
Ten ASH Presentations You Don’t Want to Miss

Cleveland Clinic oncologists’ selected abstracts

23-CNR-3741790-CQD-Hero-650×450 cell mobilization
April 24, 2023
Plerixafor is Effective for Hematopoietic Progenitor Cell Mobilization in Patients with AL Amyloidosis

On-demand stem cell mobilizer is an effective salvage strategy

CAR T-cell therapy
April 5, 2023
Insights About CAR T-Cell Therapy

Dispelling myths and sharing practical experiences

CAR T-cell therapy for multiple myeloma
March 13, 2023
Ide-CEL CAR T-Cell Therapy Effective in Multiple Myeloma Among Patients with Comorbidities

Research indicates strong rationale for expanding trial eligibility criteria

22-CNR-3245747-CQD-Hero-650×450 aplastic anemia
September 13, 2022
Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Retrospective study yields clues to understanding risk of secondary myeloid neoplasms

April 27, 2022
Hairy Cell Leukemia Complicated by Severe COVID-19: A Case Study

Novel three-drug regimen used to manage life-threatening developments

March 23, 2022
Experimental Drug Shows Promise for Alleviating Myelofibrosis-Associated Anemia

Momelotinib, a new JAK inhibitor, inches closer to market approval

Mukherjee CQD 654×450
March 8, 2022
Novel Algorithm Highlights the Burden of Idiopathic Multicentric Castleman Disease

Claims data reveal disorder is often overlooked and undertreated